

CORRECTION

COVID-19 유행 시기의 성인 염증성 장질환 임상 진료지침: 전문가 합의 권고문

박용은^{1,*}, 이유진^{2,*}, 장지영³, 송현주⁴, 김덕환⁵, 양영주⁶, 김병창⁷, 이재곤⁸, 양희찬⁹, 최미영¹⁰, 김성은^{11,**}, 명승재^{12,**}, 대한장연구학회 가이드라인 위원회

인제대학교 의과대학 해운대백병원 소화기내과¹, 계명대학교 의과대학 동산의료원 소화기내과², 이화여자대학교 의과대학 이대서울병원 건진외과³, 제주대학교 의과대학 제주대학교병원 소화기내과⁴, CHA 의과대학 분당차병원 소화기센터⁵, 한림대학교 의과대학 한림대학교 춘천성심병원 소화기내과⁶, 국립암센터 대장암센터⁷, 한림대학교 의과대학 한림대학교 동탄성심병원 소화기내과⁸, 전북대학교 의과대학 전북대학교병원 소화기내과⁹, 한국보건의료연구원 임상근거연구팀¹⁰, 이화여자대학교 의과대학 이대목동병원 소화기내과¹¹, 울산대학교 의과대학 서울아산병원 소화기내과¹²

KASID Guidance for Clinical Practice Management of Adult Inflammatory Bowel Disease during the COVID-19 Pandemic: Expert Consensus Statement

Yong Eun Park^{1,*}, Yoo Jin Lee^{2,*}, Ji Young Chang³, Hyun Joo Song⁴, Duk Hwan Kim⁵, Young Joo Yang⁶, Byung Chang Kim⁷, Jae Gon Lee⁸, Hee Chan Yang⁹, Miyong Choi¹⁰, Seong-Eun Kim^{11,**}, Seung-Jae Myung^{12,**} and The Clinical Practice Guideline Committee of the Korean Association for the Study of the Intestinal Diseases

Division of Gastroenterology, Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine¹, Busan; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Dongsan Medical Center, Keimyung University School of Medicine², Daegu; Department of Health Promotion Medicine, Ewha Womans University Seoul Hospital, Ewha Womans University College of Medicine³, Seoul; Division of Gastroenterology, Department of Internal Medicine, Jeju National University Hospital, Jeju National University College of Medicine⁴, Jeju; Digestive Disease Center, CHA Bundang Hospital, CHA University⁵, Seongnam; Division of Gastroenterology, Department of Internal Medicine, Hallym University Chuncheon Sacred Heart Hospital, Hallym University College of Medicine⁶, Chuncheon; Center for Colorectal Cancer, National Cancer Center⁷, Goyang; Division of Gastroenterology, Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hallym University College of Medicine⁸, Hwaseong; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Jeonbuk National University Hospital, Jeonbuk National University Medical School⁹, Jeonju; Division of Healthcare Technology Assessment Research, National Evidence-based Healthcare Collaborating Agency¹⁰, Seoul; Division of Gastroenterology, Department of Internal Medicine, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine¹¹, Seoul; Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine¹², Seoul, Korea

Korean J Gastroenterol 2021;78:105-116 <https://doi.org/10.4166/kjg.2021.112>

대한소화기학회지에 게재된 위 논문에서 초록을 정정합니다.

This correction is being published to correct the abstract in above article.

Before correction

The coronavirus disease 2019 (COVID-19) pandemic has reduced the ability to prevent or control chronic disease due to the concerns about safety in accessing health care. Inflammatory bowel disease (IBD) is a chronic condition requiring long- term sustained treatment, which is difficult in the current panedemic situation. The Korean Association for the Study of Intestinal Diseases (KASID) has developed an expert consensus statement on the clinical

practice management of adult inflammatory bowel disease during the COVID-19 pandemic. This expert consensus statement is based on guidelines and clinical reports from several countries around the world. It provides recommendations to deal with the risk of COVID-19 and medication use in IBD patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and emphasizes the importance of right treatment approach to avoid worsening of the disease condition in IBD patients.

After correction

Many unexpected problems have resulted from the unprecedented COVID-19 pandemic. The optimal management of patients with inflammatory bowel disease (IBD) during the COVID-19 pandemic has also been a challenge. Therefore, the Korean Association for the Study of Intestinal Diseases (KASID) developed a consensus statement of experts regarding the management of IBD during the COVID-19 pandemic. This consensus statement made recommendations regarding the risk and treatment of COVID-19 in IBD patients. This statement emphasizes that IBD is not a risk factor for COVID-19, and care should be taken not to exacerbate IBD in patients in remission state by maintaining their medications, except for corticosteroids.